Background Nonsteroidal anti-inflammatory drug (NSAID)–exacerbated respiratory disease
(N-ERD) comprises the triad of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma …

Aspirin-exacerbated respiratory disease (AERD) is characterized by the coexistence of
nasal polyps, rhinosinusitis, and asthma, which is exacerbated after the diagnostic or …

Background Omalizumab, an anti-immunoglobulin E antibody, has clinical efficacy against
respiratory symptoms of aspirin-exacerbated respiratory disease (AERD). However, some …

Background Aspirin desensitization has been associated with benefit in management of
aspirin-exacerbated respiratory disease (AERD). An intervention that would encourage …

Rationale: Aspirin-exacerbated respiratory disease is characterized by severe asthma,
nonsteroidal antiinflammatory drug hypersensitivity, nasal polyposis, and leukotriene …

Background: The current treatment for patients with aspirin-exacerbated respiratory disease
(AERD) who have uncontrolled asthma or chronic rhinosinusitis is aspirin desensitization …

Background: The association of acetylsalicylic acid (ASA) intolerance, chronic rhinosinusitis
with nasal polyps (CRSwNP), asthma, or chronic urticaria is known as NSAID-exacerbated …

Abstract Background Despite adding Omalizumab to conventional therapy, several severe
asthmatics still show poor disease control. We investigated the factors that may affect a …

Background Aspirin desensitization is an effective treatment option for aspirin-exacerbated
respiratory disease. Aspirin desensitization protocol modifications have improved the safety …

Omalizumab is a humanized monoclonal anti-IgE antibody approved in 2005 by the
European Medicine Agency (EMA) for the treatment of severe persistent allergic asthma …